NCT02961764 - Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) | Biotech Hunter

Enrollment

313

Participants

Timeline

Start Date

November 29, 2016

Primary Completion Date

March 29, 2019

Study Completion Date

March 29, 2019

Conditions

Acute Bacterial Skin and Skin Structure Infections

Interventions

DRUG

Usual Care

Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.

DRUG

Dalbavancin

Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.

Trial Locations (11)

Johns Hopkins Hospital, Baltimore

Tampa General Hospital, Tampa

ProMedica Monroe Regional Hospital, Monroe

Henry Ford Hospital, Detroit

Wayne State University, Detroit

Rush University Medical Center, Chicago

Truman Medical Centers, Kansas City

Maricopa Medical Center, Phoenix

Olive View-UCLA Medical Center, Sylmar

Hartford Hospital, Hartford

University of Massachusetts, Worcester